{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:06:19Z","timestamp":1790885179304,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Talquetamab is the first approved G protein\u2013coupled receptor family C group 5 member D\u2013targeting bispecific antibody for the treatment of triple\u2010class exposed relapsed\/refractory multiple myeloma (RRMM) on the basis of results from the phase 1\/2 MonumenTAL\u20101 study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifiers NCT03399799 and NCT04634552). This study describes patient\u2010reported outcomes (PROs) among patients who received talquetamab in MonumenTAL\u20101.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PROs were assessed in phase 2 of MonumenTAL\u20101. Patients had RRMM with \u22653 prior lines of therapy (proteasome inhibitors, immunomodulatory drugs, and anti\u2010CD38 antibodies). Patients included in these analyses received talquetamab 0.8 mg\/kg every other week. PRO assessments included European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ\u2010C30), EuroQol 5\u2010Dimension 5\u2010Level Visual Analogue Scale (EQ\u20105D\u20105L VAS), and Patient Global Impression of Severity (PGIS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As of January 29, 2024, PRO data were available for 118 patients who received \u22651 dose of talquetamab. Compliance for completion was &gt;95% of patients at baseline and &gt;80% at most posttreatment visits. After an initial worsening in most PROs from baseline through cycle 1, patients reported improvements with continued treatment. At cycle 21, least\u2010squares mean change from baseline showed improvements in global health status (4.9 points) and emotional functioning (12.5 points), along with reductions in pain (11.4 points) and fatigue (4.0 points). The proportion of patients with clinically meaningful improvements or no change from baseline increased throughout treatment. EQ\u20105D\u20105L VAS and PGIS scores demonstrated improvement in health\u2010related quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These PRO results complement the efficacy and safety profile of talquetamab, which highlights talquetamab as a viable treatment option for patients with triple\u2010class exposed RRMM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35927","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:00:20Z","timestamp":1752066020000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Talquetamab improves patient\u2010reported symptoms and health\u2010related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1\/2 MonumenTAL\u20101 study"],"prefix":"10.1002","volume":"131","author":[{"given":"Carolina","family":"Schinke","sequence":"first","affiliation":[{"name":"Myeloma Center University of Arkansas for Medical Sciences  Little Rock Arkansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras Hospital Germans Trias i Pujol  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca Centro de Investigaci\u00f3n del C\u00e1ncer, IBMCC\u2010USAL, CSIC  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute  Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"University Hospital of W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Kato","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacheeta","family":"Bathija","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva G.","family":"Katz","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campagna","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi W.","family":"Hilder","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalmer","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital Hotel\u2010Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San\u2010Miguel","sequence":"additional","affiliation":[{"name":"Cancer Center Cl\u00ednica Universidad de Navarra CIMA CIBERONC IDISNA  Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez\u2010Otero","sequence":"additional","affiliation":[{"name":"Cancer Center Cl\u00ednica Universidad de Navarra CIMA CIBERONC IDISNA  Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Program University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010020\u201005493\u2010y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010015\u20102644\u20106"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u20106637\u20106"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102017.1.508"},{"key":"e_1_2_9_11_1","volume-title":"Prescribing Information","author":"TALVEY (talquetamab\u2010tgvs)","year":"2023"},{"key":"e_1_2_9_12_1","volume-title":"Prescribing Information","author":"TALVEY (talquetamab)","year":"2023"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","unstructured":"RascheL SchinkeCD TouzeauC et\u00a0al.Long\u2010term efficacy and safety results from the phase 1\/2 MonumenTAL\u20101 study of talquetamab a GPRC5D\u00d7CD3 bispecific antibody in patients with relapsed\/refractory multiple myeloma [poster P915]. Poster presented at: European Hematology Association 2024 Hybrid Congress; June 13\u201316 2024; Madrid Spain.","DOI":"10.1016\/S2152-2650(24)00976-5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010189151"},{"key":"e_1_2_9_16_1","volume-title":"Poster presented at: 64th American Society of Hematology Annual Meeting","author":"Touzeau C","year":"2022"},{"key":"e_1_2_9_17_1","unstructured":"SchinkeCD TouzeauC MinnemaMC et\u00a0al.Pivotal phase 2 MonumenTAL\u20101 results of talquetamab a GPRC5D\u00d7CD3 bispecific antibody for relapsed\/refractory multiple myeloma [poster 8036]. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2\u20136 2023; Chicago IL."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201010\u2010299487"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_9_21_1","volume-title":"EORTC QLQ\u2010C30 Scoring Manual","author":"Fayers P","year":"2001"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010018\u20103469\u20104"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074534"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102141.1996.352889.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010011\u20109903\u2010x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.05.008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834010395342"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20105\u201070"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.11.008"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010016\u20102410\u20102"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100609.2009.01250.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010022\u201006979\u20107"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7561"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20103667"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","unstructured":"PopatR LaheijA van deDonkNWCJ et\u00a0al.Prophylactic interventions for oral toxicities with the GPRC5D\u00d7CD3 bispecific antibody talquetamab in relapsed\/refractory multiple myeloma: an open\u2010label phase 2 randomized study (TALISMAN) [poster P066]. Poster presented at: 21st International Myeloma Society Annual Meeting; September 25\u201328 2024; Rio de Janeiro Brazil.","DOI":"10.1016\/S2152-2650(24)01969-4"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:20:27Z","timestamp":1760293227000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,15]]}},"alternative-id":["10.1002\/cncr.35927"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35927","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"2024-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35927"}}